Literature DB >> 35298

Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin.

E E Ohnhaus, B Kirchhof, E Peheim.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 35298     DOI: 10.1002/cpt1979255part1591

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  16 in total

1.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

Authors:  E Perucca; R Grimaldi; G M Frigo; A Sardi; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  A possible drug interaction between rifampicin and enalapril.

Authors:  D Kandiah; W J Penny; A G Fraser; M J Lewis
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects.

Authors:  E Perucca; M Ruprah; A Richens; B K Park; D J Betteridge; A M Hedges
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

4.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

5.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.

Authors:  P V Luoma; E A Sotaniemi; R O Pelkonen; A Arranto; C Ehnholm
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 7.  Drug interactions with St John's wort : mechanisms and clinical implications.

Authors:  Marcus Mannel
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  Bioavailability and elimination of nitrendipine in liver disease.

Authors:  P Dylewicz; W Kirch; S R Santos; H J Hutt; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.

Authors:  W Kirch; I Rose; H G Demers; G Leopold; J Pabst; E E Ohnhaus
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

10.  Interaction between the beta-adrenoceptor blockers metoprolol and atenolol with amitriptyline and their effects on oxidative liver metabolism.

Authors:  W Kirch; H Spahn; N R Kitteringham; H J Hutt; E Mutschler; E E Ohnhaus
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.